Results 31 to 40 of about 1,588,451 (244)
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid cells that are closely related to tumor immune escape, but the mechanism by which MDSCs regulate B cells has not been elucidated.
Min Liu +9 more
doaj +1 more source
Directed Evolution of PD-L1-Targeted Affibodies by mRNA Display
Therapeutic monoclonal antibodies directed against PD-L1 (e.g., atezolizumab) disrupt PD-L1:PD-1 signaling and reactivate exhausted cytotoxic T-cells in the tumor compartment.
Brian J. Grindel (9407114) +10 more
core +1 more source
Background Previous studies have shown clinical relevance of programmed death-ligand 1 (PD-L1) and soluble PD-L1 (sPD-L1) in human cancers. However, still contradictory results exist.
Karolina Okła +8 more
doaj +1 more source
PD-L1 blockade enhances anti-tumor efficacy of NK cells
Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited to ~ 15% of patients with lymphocyte infiltrated, PD-L1 positive tumors.
Jeremiah L. Oyer +3 more
doaj +1 more source
Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave
Programmed death-ligand 1 (PD-L1) is one of the most classic immune checkpoint molecules. Cancer cells express PD-L1 to inhibit the activity of effector T cells’ cytotoxicity through programmed death 1 (PD-1) engagement in exposure to inflammatory ...
Xinfang Yu +3 more
doaj +1 more source
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
PD-1–PD-L1 interaction is known to drive T cell dysfunction, which can be blocked by anti-PD-1/PD-L1 antibodies. However, studies have also shown that the function of the PD-1–PD-L1 axis is affected by the complex immunologic regulation network, and some
Zijun Y. Xu-Monette +4 more
doaj +1 more source
Figure S1. Anti-PD-L1 antibody exhibited in vivo activity on GV369-CON B-cell lymphoma. A and B: CD8+T cell percentage was enhanced, as well as CD8+T cell apoptosis and Fas expression were inhibited in GV369-CON group treated with anti-PD-L1 antibody.
Hui-Juan Zhong (799289) +9 more
core +1 more source
It has been reported that mismatch repair deficient (d-MMR) tumors show sensitivity to immune checkpoint inhibitors. We aimed to evaluate the correlation of d-MMR and PD-1/PD-L1 expression in invasive urothelial carcinoma of the bladder.
Kıran, Merve M. +3 more
core +1 more source
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death protein 1 (PD‐1)/programmed cell death 1 ligand 1 (PD‐L1) pathway have transformed urothelial cancer (UC) therapy.
Anna Hernández‐Prat +16 more
doaj +1 more source
The function and regulation of PD-L1 in immunotherapy
PD-L1, also known as B7-H1, is a type I transmembrane protein, which is expressed in different kinds of tumor cells. It is correlated with poor clinical outcome of patients with various types of tumors.
Libin Guo, Yao Lin, Hang Fai Kwok
doaj +1 more source

